16800 West Twelve Mile Road
Suite 201, Southfield, MI 48076

Spinning Globe

DNA Design

News

Bristol Myers Squibb Licenses Core Drug Discovery Technology Platform From Housey Pharma

Bristol Myers Squibb (“BMS”), one of the world’s leading oncology companies, has entered into a license agreement with Housey Pharma to license its core enabling technologies for new drug discovery directed toward difficult and “undruggable” targets in the human genome.  This highly promising area of research in medicine may lead to a host of novel treatments for diseases such as drug-resistant cancers, diabetes, cardiovascular disease, CNS disorders such as dementia, and many other disease states for which current technologies are lacking.

“We are pleased to share this core technology with our scientific colleagues at Bristol Myers Squibb.  We are excited by the use of these technologies throughout the industry in the in search for new medicines that will benefit people around the world,” said Dr. Gerard Housey, M.D., Ph.D., President and CEO of Housey Pharma.

F. Hoffman-La Roche and Johnson & Johnson License Patented Drug-Discovery Platform Technologies from Housey Pharma

Housey Pharma has entered into license agreements of its core-enabling technologies for new-drug discovery with the world’s two largest research-based pharmaceutical companies, F. Hoffman-La Roche (“Roche”) and the Janssen Research & Development subsidiary of Johnson & Johnson (“J&J”).  This highly promising area of research in medicine may lead to a host of novel treatments for diseases such as drug-resistant cancers, diabetes, cardiovascular disease, CNS disorders such as dementia, and many other disease states for which current technologies were lacking.

Both Roche, based in Basel, Switzerland, and J&J’s Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with Housey Pharma’s HMI subsidiary to gain access to its core-enabling technology for new-drug discovery and development.  Both Roche and J&J have annual Research and Development spending in excess of US $10 billion.

“Breakthroughs in the discovery and development of new medicines are enabled through the use of this advanced technology platform,” said Dr. Gerard Housey, M.D., Ph.D., President and CEO of Housey Pharma.   “We look forward to seeing innovative new medicines that benefit people around the world brought forth by our scientific colleagues at Roche and J&J. These companies have been at the forefront of innovations in medicine ranging from new treatments in oncology to COVID-19 vaccines.”

https://www.prweb.com/releases/f_hoffmann_la_roche_and_johnson_johnson_license_patented_drug_discovery_platform_technologies_from_housey_pharma/prweb17312973.htm/

Therapeutic Discovery Tax Grants Awarded

HPRL Awarded Qualifying Therapeutic Discovery Tax Grants for two of its on-going research programs; “Novel Inhibitors for the Treatment of Highly Drug-Resistant Chronic Myelogenous Leukemia” and “Discovery and Development of Anti-Diabetic Drugs.”